Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-25
2008-11-11
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C544S369000, C544S357000, C548S204000, C548S236000
Reexamination Certificate
active
07449468
ABSTRACT:
The present invention provides a compound of formula (I):wherein R1-R5, R25, R26, Y, y, and X2are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.
REFERENCES:
patent: 5972881 (1999-10-01), Heyman et al.
patent: 6518290 (2003-02-01), Sierra
patent: 6710063 (2004-03-01), Chao et al.
patent: 6723740 (2004-04-01), Chao et al.
patent: 7153878 (2006-12-01), Conner et al.
patent: 7259175 (2007-08-01), Conner et al.
patent: 2004/0077659 (2004-04-01), Oliver
patent: 0008002 (2000-02-01), None
patent: 0100603 (2001-01-01), None
patent: 01/40207 (2001-06-01), None
patent: 0140207 (2001-06-01), None
patent: 01/00603 (2001-12-01), None
patent: 0250048 (2002-06-01), None
patent: 0262774 (2002-08-01), None
Berger et al.; “The Mechanisms of Action of PPARs”; Annu. Rev. Med.; 2002; vol. 53; pp. 409-435.
Bishop-Bailey; “Peroxisome Proliferator Activated Receptors in the Cardiovascular System”; British Journal of Pharmacology; 2000; vol. 129, No. 5; pp. 823-834.
Ellis et al.; “Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease”; Arch. Dermatol.; 2000; vol. 136; pp. 609-616.
Lehmann et al.; “An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor Gamma”; Journal of Biological Chemistry; 1995; vol. 270, No. 22; pp. 12953-12956.
Mae et al.; “A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptory Ligand-Binding Activity Affects Diabetes in KK-A[y] Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mica and Hypertension in Spontaneously Hypertensive Rats”; Journal of Nutrition; 2003; vol. 133, No. 11; pp. 3369-3377.
Miyachi et al.; “Nucleophilic Group Transfer Reactivity for Fibric Acid Derived Drug Molecules”; Expert Opin. Ther. Patents; 2004; vol. 14, pp. 607-618.
Mukherjee et al.; “Nuclear Receptors in Metabolic Diseases”; Emerging Therapeutic Targets; 2000; vol. 4; pp. 377-396.
Oliver et al.; “A Selective Peroxisome Proliferator-Activated Receptor Delta Agonist Promotes Reverse Cholesterol Transport”; Proceedings of the National Academy of Sciences of the USA; 2001; vol. 98, No. 9; pp. 5306-5311.
Rami et al.; “Synthetic Ligands for PPAR: Review of Patent Literature 1994-1999”; Exp. Opin. Ther. Patents; 2000; vol. 10; pp. 623-634.
Vippagunta et al.; “Crystalline Solids”; Advanced Drug Delivery Reviews; 2001; vol. 48; pp. 3-26.
Banker Pierette
Cadilla Rodolfo
Lambert, III Millard Hurst
Rafferty Stephen William
Sternbach Daniel David
Bernhardt Emily
Brink Robert H.
SmithKline Beecham Corporation
LandOfFree
Thiazole and oxazole derivatives as activators of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazole and oxazole derivatives as activators of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazole and oxazole derivatives as activators of human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034496